Currently out of the existing stock ratings of Steven Lichtman, 115 are a BUY (88.46%), 15 are a HOLD (11.54%).

Steven Lichtman

Work Performance Price Targets & Ratings Chart

Analyst Steven Lichtman, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 60.56% that have a potential upside of 25.25% achieved within 158 days.

Steven Lichtman’s has documented 281 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on DXCM, DexCom at 25-Oct-2024.

Wall Street Analyst Steven Lichtman

Analyst best performing recommendations are on TNDM (TANDEM DIABETES CARE).
The best stock recommendation documented was for TNDM (TANDEM DIABETES CARE) at 2/27/2019. The price target of $68 was fulfilled within 2 days with a profit of $6.14 (9.93%) receiving and performance score of 49.63.

Average potential price target upside

of $24.08 (14.76%) on PODD (INSULET).
of $20.09 (17.64%) on ZBH (ZIMMER BIOMET HOLDINGS).
of $18.87 (10.79%) on SYK (STRYKER).

BSX Boston Scientific Corp DXCM DexCom ELGX Endologix GKOS Glaukos Corp GMED Globus Medical IART Integra LifeSciences Holdings MDT Medtronic PLC ORGO Organogenesis Holdings PODD Insulet SYK Stryker TNDM Tandem Diabetes Care ZBH Zimmer Biomet Holdings ALC Alcon AG CFMS ConforMIS COO The Cooper Companies Common Stock MMSI Merit Medical Systems MNKD MannKind Corp BWAY Brainsway Ltd RXST Rxsight MODD Modular Medical

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Matt Miksic (BARCLAYS)